Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 113

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 113
---
 of detection was 0.250 ng/mL). For the reference control animals, all animals had detectable concentrations of doxorubicin for up to 8 hours post dose administration. |     | D-MNA doses of                                                                                                                                               
 up to 200 µg per week for three doses total were well tolerated. Tissue reactions were limited to inflammatory reactions of the dermis at the treated sites. |
| Immunotoxi-cology (LLNA Pilot): BRT Study 20170724                                                                                                               |     | 21-Feb-2018 |     | CBA/J Mice 8- weeks old; 2F per group N =8    |     | 25, 50, 100, 200 µg/ear modified D- MNA gel + DMSO |     | Days 1-3   |     | Topical gel (both ears) |     | Modified D-MNA gel + DMSO was applied for three days and ear thickness and irritation were determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |     | None had ≥ 25% increase of ear thickness or skin irritation.                                                                                                 |
| Doxorubicin-Containing Microneedle Array (D-MNA) Constituents (Doxorubicin and Carboxymethyl Cellulose): Local Lymph Node Assay(LLNA) in Mice BRT Study 20170725 |     | 28-Feb-2018 |     | CBA/J Mice 8-weeks old; 5-8F per group N = 45 |     | 25, 50, 100, 200 µg/ear modified D- MNA gel + DMSO |     | Days 1-3   |     | Topical gel (both ears) |     | GLP. Standard test for sensitization potential of doxorubicin using modified D-MNA gel + DMSO. There were no clinical signs and no noteworthy body weight changes. Change in ear thickness was <25%. It was not possible to calculate an EC3 value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |     | Modified D-MNA gel + DMSO was not considered a sensitizer.                                                                                                   |

<div align='center'>77</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

| Study                                                              |     | Start Date  |     | Model